[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557927":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":67,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":66,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":66,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":49,"whyStopped":66,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral estrogen treatment","ACTIVE_COMPARATOR","Turner syndrome patients receiving oral estrogen treatment (Estrofem®)",[13],"Drug: 17-beta estradiol",{"label":15,"type":10,"description":16,"interventionNames":17},"Transdermal estrogen treatment","Turner syndrome patients receiving transdermal estrogen treatment (Divigel)",[13],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","17-beta estradiol","Treatment with orally administered estrogen for 14 days",[9],[25],"Estrofem",{"type":20,"name":21,"description":27,"armGroupLabels":28,"otherNames":29},"Treatment with transdermally administered estrogen for 14 days",[15],[30],"Divigel",[32],{"name":33,"affiliation":34,"role":35},"Claus H Gravholt, Professor","Aarhus University Hospital","PRINCIPAL_INVESTIGATOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Camilla M Balle, Ph.d.-student","CONTACT","40769623","0045","camibl@clin.au.dk",{"name":33,"role":39,"phone":44,"phoneExt":41,"email":45},"78455470","claus.gravholt@clin.au.dk",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Department of Endocrinology and Internal Medicine, Aarhus University Hospital","RECRUITING","Aarhus","Aarhus N","8200","Denmark","DK",{"type":56,"coordinates":57},"Point",[58,59],10.21076,56.15674,{"lat":59,"lon":58},[62],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":63},"camibl@rm.dk",{"type":65,"investigatorFullName":66,"investigatorTitle":66,"investigatorAffiliation":66,"oldNameTitle":66,"oldOrganization":66},"SPONSOR",null,[68],{"name":5,"class":6},"100557927","phase-4-determining-dose-equivalence-between-oral-and-transdermal-estrogen-treatment-in-women-with-turner-syndrome-100557927",false,"NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study","Inclusion Criteria:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nExclusion Criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy","FEMALE","18 Years","50 Years",{"count":80,"type":81},50,"ESTIMATED","INTERVENTIONAL",[84],"PHASE4","This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.",[87,88,89,90,91],"Turner Syndrome","Hypogonadism; Ovarian","Hormone Replacement Therapy","Estrogen Replacement Therapy","Estrogen Deficiency",[93,89,90,94,95],"Turner syndrome","Estrogen treatment","Dose equipotency","2024-08-22",{"date":98,"type":99},"2024-08-23","ACTUAL",{"date":101,"type":99},"2021-11-29",{"date":103,"type":81},"2026-12-31",{"name":34,"class":6},1]